IL129558A - תולדות אפותילון ותכשירי רוקחות ותכשירים להגנת צמחים המכילים אותן - Google Patents

תולדות אפותילון ותכשירי רוקחות ותכשירים להגנת צמחים המכילים אותן

Info

Publication number: IL129558A
Authority: IL; Israel
Prior art keywords: epothilone; methanol; culture; compositions; epothilones
Prior art date: 1996-11-18

Application number

IL12955897A

Other languages

English (en)

Other versions

IL129558A0 (en

Original Assignee

Biotechnolog Forschung Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-18

Filing date

1997-11-18

Publication date

2001-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26031383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL129558(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-11-18 Application filed by Biotechnolog Forschung Gmbh filed Critical Biotechnolog Forschung Gmbh

2000-02-29 Publication of IL129558A0 publication Critical patent/IL129558A0/xx

2001-10-31 Publication of IL129558A publication Critical patent/IL129558A/he

Links

239000000203 mixture Substances 0.000 title claims description 16
150000003883 epothilone derivatives Chemical class 0.000 title claims description 14
229930013356 epothilone Natural products 0.000 claims abstract description 30
BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 claims abstract description 10
BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 claims abstract description 10
XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 claims abstract description 9
XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 claims abstract description 9
BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 claims abstract description 9
XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 claims abstract description 8
150000001875 compounds Chemical class 0.000 claims description 16
239000003085 diluting agent Substances 0.000 claims description 4
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims description 3
239000000824 cytostatic agent Substances 0.000 claims description 2
230000001085 cytostatic effect Effects 0.000 claims description 2
238000003898 horticulture Methods 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims description 2
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 claims 2
HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 abstract description 40
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 30
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
239000011347 resin Substances 0.000 description 18
229920005989 resin Polymers 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
239000003480 eluent Substances 0.000 description 14
FCCNKYGSMOSYPV-DEDISHTHSA-N (-)-Epothilone E Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C FCCNKYGSMOSYPV-DEDISHTHSA-N 0.000 description 12
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
230000036983 biotransformation Effects 0.000 description 12
FCCNKYGSMOSYPV-UHFFFAOYSA-N epothilone E Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2OC2CC1C(C)=CC1=CSC(CO)=N1 FCCNKYGSMOSYPV-UHFFFAOYSA-N 0.000 description 12
FCCNKYGSMOSYPV-OKOHHBBGSA-N epothilone e Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 FCCNKYGSMOSYPV-OKOHHBBGSA-N 0.000 description 12
UKIMCRYGLFQEOE-RLHMMOOASA-N (-)-Epothilone F Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C UKIMCRYGLFQEOE-RLHMMOOASA-N 0.000 description 9
UKIMCRYGLFQEOE-UHFFFAOYSA-N Epothilone F Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2(C)OC2CC1C(C)=CC1=CSC(CO)=N1 UKIMCRYGLFQEOE-UHFFFAOYSA-N 0.000 description 9
238000001514 detection method Methods 0.000 description 9
UKIMCRYGLFQEOE-RGJAOAFDSA-N epothilone f Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 UKIMCRYGLFQEOE-RGJAOAFDSA-N 0.000 description 9
238000004128 high performance liquid chromatography Methods 0.000 description 9
239000012071 phase Substances 0.000 description 9
QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 8
239000000287 crude extract Substances 0.000 description 8
QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 8
238000000855 fermentation Methods 0.000 description 7
230000004151 fermentation Effects 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
230000008033 biological extinction Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
150000002500 ions Chemical class 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000003921 oil Substances 0.000 description 5
238000006116 polymerization reaction Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
101150041968 CDC13 gene Proteins 0.000 description 4
201000009030 Carcinoma Diseases 0.000 description 4
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
239000005030 aluminium foil Substances 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
239000002609 medium Substances 0.000 description 4
238000000034 method Methods 0.000 description 4
238000001228 spectrum Methods 0.000 description 4
238000005507 spraying Methods 0.000 description 4
239000001117 sulphuric acid Substances 0.000 description 4
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
241000196324 Embryophyta Species 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
244000068988 Glycine max Species 0.000 description 3
235000010469 Glycine max Nutrition 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
239000001110 calcium chloride Substances 0.000 description 3
229910001628 calcium chloride Inorganic materials 0.000 description 3
235000011148 calcium chloride Nutrition 0.000 description 3
229940041514 candida albicans extract Drugs 0.000 description 3
235000013312 flour Nutrition 0.000 description 3
239000008103 glucose Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
238000012216 screening Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000012138 yeast extract Substances 0.000 description 3
LMSDCGXQALIMLM-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;iron Chemical compound [Fe].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O LMSDCGXQALIMLM-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
-1 CH3 Epothilones Chemical group 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
241001532577 Sorangium Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
102000004243 Tubulin Human genes 0.000 description 2
108090000704 Tubulin Proteins 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
210000003679 cervix uteri Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000012505 colouration Methods 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
238000001212 derivatisation Methods 0.000 description 2
FFHWGQQFANVOHV-UHFFFAOYSA-N dimethyldioxirane Chemical compound CC1(C)OO1 FFHWGQQFANVOHV-UHFFFAOYSA-N 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000010828 elution Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
244000005700 microbiome Species 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
239000000047 product Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
241000862997 Sorangium cellulosum Species 0.000 description 1
241000282887 Suidae Species 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
238000005273 aeration Methods 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
239000012491 analyte Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000009295 crossflow filtration Methods 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
150000002118 epoxides Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
150000004965 peroxy acids Chemical class 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
239000013587 production medium Substances 0.000 description 1
125000002577 pseudohalo group Chemical group 0.000 description 1
238000007873 sieving Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
VAVPGQSSOJBZIP-UHFFFAOYSA-N sodium;iron(3+) Chemical compound [Na+].[Fe+3] VAVPGQSSOJBZIP-UHFFFAOYSA-N 0.000 description 1
239000002689 soil Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
- A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Biotechnology (AREA)
Environmental Sciences (AREA)
Dentistry (AREA)
Agronomy & Crop Science (AREA)
Pest Control & Pesticides (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Oncology (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Silicon Polymers (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Epoxy Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Steroid Compounds (AREA)

IL12955897A 1996-11-18 1997-11-18 תולדות אפותילון ותכשירי רוקחות ותכשירים להגנת צמחים המכילים אותן IL129558A (he)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19647580		1996-11-18
DE19707506		1997-02-25
PCT/EP1997/006442 WO1998022461A1 (de)	1996-11-18	1997-11-18	Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel

Publications (2)

Publication Number	Publication Date
IL129558A0 IL129558A0 (en)	2000-02-29
IL129558A true IL129558A (he)	2001-10-31

Family

ID=26031383

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12955897A IL129558A (he)	1996-11-18	1997-11-18	תולדות אפותילון ותכשירי רוקחות ותכשירים להגנת צמחים המכילים אותן

Country Status (23)

Country	Link
US (6)	US7067544B2 (he)
EP (2)	EP0941227B2 (he)
JP (1)	JP4274583B2 (he)
KR (1)	KR100538095B1 (he)
CN (2)	CN100344627C (he)
AT (2)	ATE267197T1 (he)
AU (1)	AU753546B2 (he)
BR (1)	BR9713363B1 (he)
CA (1)	CA2269118C (he)
CY (1)	CY2542B1 (he)
CZ (2)	CZ303422B6 (he)
DE (2)	DE59712968D1 (he)
DK (2)	DK1367057T3 (he)
ES (2)	ES2312695T3 (he)
HU (1)	HU229833B1 (he)
IL (1)	IL129558A (he)
NO (1)	NO319984B1 (he)
NZ (1)	NZ335383A (he)
PL (1)	PL193229B1 (he)
PT (2)	PT1367057E (he)
RU (1)	RU2198173C2 (he)
TW (1)	TW408119B (he)
WO (1)	WO1998022461A1 (he)

Families Citing this family (186)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE59609305D1 (de)	1995-11-17	2002-07-11	Biotechnolog Forschung Gmbh	Epothilon-Derivate und deren Herstellung
US5969145A (en) *	1996-08-30	1999-10-19	Novartis Ag	Process for the production of epothilones and intermediate products within the process
ATE267197T1 (de) *	1996-11-18	2004-06-15	Biotechnolog Forschung Gmbh	Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6867305B2 (en)	1996-12-03	2005-03-15	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
EP1386922B1 (en)	1996-12-03	2012-04-11	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en)	1996-12-13	2003-12-09	The Scripps Research Institute	Epothilone analogs
US6441186B1 (en) *	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US6380394B1 (en)	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
US6320045B1 (en)	1997-12-04	2001-11-20	Bristol-Myers Squibb Company	Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en)	1997-12-04	2002-04-02	Bristol-Myers Squibb Company	Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6683100B2 (en)	1999-01-19	2004-01-27	Novartis Ag	Organic compounds
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr)	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en)	1998-04-21	2002-12-24	Bristol-Myers Squibb Company	2,3-olefinic epothilone derivatives
US6399638B1 (en)	1998-04-21	2002-06-04	Bristol-Myers Squibb Company	12,13-modified epothilone derivatives
DE19820599A1 (de)	1998-05-08	1999-11-11	Biotechnolog Forschung Gmbh	Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
NZ508326A (en) *	1998-06-18	2003-10-31	Novartis Ag	A polyketide synthase and non ribosomal peptide synthase genes, isolated from a myxobacterium, necessary for synthesis of epothiones A and B
DE19826988A1 (de)	1998-06-18	1999-12-23	Biotechnolog Forschung Gmbh	Epothilon-Nebenkomponenten
DE19846493A1 (de) *	1998-10-09	2000-04-13	Biotechnolog Forschung Gmbh	DNA-Sequenzen für die enzymatische Synthese von Polyketid- oder Heteropolyketidverbindungen
US6410301B1 (en)	1998-11-20	2002-06-25	Kosan Biosciences, Inc.	Myxococcus host cells for the production of epothilones
CN100381566C (zh)	1998-11-20	2008-04-16	科森生物科学公司	产生环氧噻酮及其衍生物的重组方法和材料
HK1040739A1 (zh) *	1998-12-23	2002-06-21	Bristol-Myers Squibb Company	微生物转形方法，用以制造epothilone
US6780620B1 (en)	1998-12-23	2004-08-24	Bristol-Myers Squibb Company	Microbial transformation method for the preparation of an epothilone
US6596875B2 (en)	2000-02-07	2003-07-22	James David White	Method for synthesizing epothilones and epothilone analogs
EE04852B1 (et)	1999-02-22	2007-06-15	Gesellschaft Fuer Biotechnologische Forschung Mbh	C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel
US6291684B1 (en)	1999-03-29	2001-09-18	Bristol-Myers Squibb Company	Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
CA2366932C (en)	1999-04-15	2009-08-25	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
JP4776843B2 (ja)	1999-10-01	2011-09-21	イムノゲンインコーポレーティッド	免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
US6518421B1 (en)	2000-03-20	2003-02-11	Bristol-Myers Squibb Company	Process for the preparation of epothilone analogs
US6593115B2 (en)	2000-03-24	2003-07-15	Bristol-Myers Squibb Co.	Preparation of epothilone intermediates
US6998256B2 (en)	2000-04-28	2006-02-14	Kosan Biosciences, Inc.	Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate
US6589968B2 (en)	2001-02-13	2003-07-08	Kosan Biosciences, Inc.	Epothilone compounds and methods for making and using the same
WO2001083800A2 (en) *	2000-04-28	2001-11-08	Kosan Biosciences, Inc.	Heterologous production of polyketides
UA75365C2 (en)	2000-08-16	2006-04-17	Bristol Myers Squibb Co	Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
GB0029895D0 (en)	2000-12-07	2001-01-24	Novartis Ag	Organic compounds
DE60225666T2 (de)	2001-01-25	2009-04-16	Bristol-Myers Squibb Co.	Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
SK8552003A3 (en)	2001-01-25	2004-06-08	Bristol Myers Squibb Co	Parenteral formulation containing epothilone analogs
NZ526871A (en) *	2001-01-25	2006-01-27	Bristol Myers Squibb Co	Pharmaceutical dosage forms of epothilones for oral administration
US6893859B2 (en)	2001-02-13	2005-05-17	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
EE200300397A (et)	2001-02-20	2003-12-15	Bristol-Myers Squibb Company	Epotilooni derivaadid refraktaarsete kasvajate raviks
IL156988A0 (en)	2001-02-20	2004-02-08	Bristol Myers Squibb Co	Pharmaceutical compositions containing epothilone derivatives
PL207197B1 (pl)	2001-02-27	2010-11-30	Novartis Ag	Połączenie obejmujące inhibitor przekazywania sygnału i pochodną epotylonową, kompozycja farmaceutyczna zawierająca to połączenie oraz zastosowanie połączenia
ATE335746T1 (de)	2001-02-27	2006-09-15	Biotechnolog Forschung Gmbh	Verfahren zur herstellung von epothilonen
ATE554756T1 (de)	2001-03-14	2012-05-15	Bristol Myers Squibb Co	Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
US6800653B2 (en)	2001-06-01	2004-10-05	Bristol-Myers Squibb Compnay	Epothilone derivatives
TWI315982B (en)	2001-07-19	2009-10-21	Novartis Ag	Combinations comprising epothilones and pharmaceutical uses thereof
DE10138347A1 (de) *	2001-08-03	2003-02-27	Schering Ag	Geschützte 3,5-Dihydroxy-2,2-dimethyl-valeronitrile für die Synthese von Epothilonen- und Derivaten und Verfahren zur Herstellung
TWI287986B (en) *	2001-12-13	2007-10-11	Novartis Ag	Use of Epothilones for the treatment of the carcinoid syndrome
US6884608B2 (en)	2001-12-26	2005-04-26	Bristol-Myers Squibb Company	Compositions and methods for hydroxylating epothilones
AU2003235761A1 (en)	2002-01-14	2003-07-24	Novartis Ag	Combinations comprising epothilones and anti-metabolites
TW200303202A (en)	2002-02-15	2003-09-01	Bristol Myers Squibb Co	Method of preparation of 21-amino epothilone derivatives
AU2003218110A1 (en)	2002-03-12	2003-09-29	Bristol-Myers Squibb Company	C3-cyano epothilone derivatives
US7211593B2 (en)	2002-03-12	2007-05-01	Bristol-Myers Squibb Co.	C12-cyano epothilone derivatives
TW200403994A (en)	2002-04-04	2004-03-16	Bristol Myers Squibb Co	Oral administration of EPOTHILONES
TW200400191A (en)	2002-05-15	2004-01-01	Bristol Myers Squibb Co	Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en)	2002-05-17	2008-07-29	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
WO2003105828A1 (en)	2002-06-14	2003-12-24	Bristol-Myers Squibb Company	Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US7507564B2 (en) *	2002-07-29	2009-03-24	Optimer Pharmaceuticals, Inc.	Tiacumicin production
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
ATE350383T1 (de) *	2002-08-23	2007-01-15	Sloan Kettering Inst Cancer	Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
HRP20050278A2 (en) *	2002-09-23	2005-10-31	Bristol-Myers Squibb Company	Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
ES2279139T3 (es) *	2002-10-15	2007-08-16	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Uso de los derivados de epotilona para el tratamiento del hiperparatiroidismo.
EP1567487A4 (en)	2002-11-15	2005-11-16	Bristol Myers Squibb Co	OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
CN100359014C (zh) *	2003-01-28	2008-01-02	北京华昊中天生物技术有限公司	一类新型埃坡霉素化合物及其制备方法和用途
US20050171167A1 (en)	2003-11-04	2005-08-04	Haby Thomas A.	Process and formulation containing epothilones and analogs thereof
EP1559447A1 (en)	2004-01-30	2005-08-03	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US7820702B2 (en)	2004-02-04	2010-10-26	Bristol-Myers Squibb Company	Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en)	2004-03-01	2008-05-27	Bristol-Myers Squibb Company	Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en)	2004-03-04	2010-04-13	Bristol-Myers Squibb Company	Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en)	2004-03-04	2009-12-01	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
PL2253614T3 (pl)	2004-04-07	2013-03-29	Novartis Ag	Inhibitory IAP
US8232244B2 (en)	2007-02-08	2012-07-31	The Board Of Trustees Of The University Of Illinois	Compositions and methods to prevent cancer with cupredoxins
US10675326B2 (en)	2004-10-07	2020-06-09	The Board Of Trustees Of The University Of Illinois	Compositions comprising cupredoxins for treating cancer
WO2006055742A1 (en) *	2004-11-18	2006-05-26	Bristol-Myers Squibb Company	Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
SI1817013T1 (sl) *	2004-11-18	2008-12-31	Bristol Myers Squibb Co	Peleta z gastrorezistentno oblogo, ki vsebuje iksabepilon
US20060121511A1 (en)	2004-11-30	2006-06-08	Hyerim Lee	Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
EP1996550A2 (en)	2005-09-27	2008-12-03	Novartis AG	Carboxyamine compounds and their use in the treatment of hdac dependent diseases
PT2275103E (pt)	2005-11-21	2014-07-24	Novartis Ag	Inibidores de mtor para o tratamento de tumores endócrinos
GB0605120D0 (en)	2006-03-14	2006-04-26	Novartis Ag	Organic Compounds
CA2647565A1 (en)	2006-03-31	2007-10-18	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
CA2645633A1 (en)	2006-04-05	2007-11-01	Novartis Ag	Combinations of therapeutic agents for treating cancer
RU2452492C2 (ru)	2006-04-05	2012-06-10	Новартис Аг	КОМБИНАЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ Bcr-Abl/c-Kit/PDGF-R TK, ДЛЯ ЛЕЧЕНИЯ РАКА
JP2009536180A (ja)	2006-05-09	2009-10-08	ノバルティスアクチエンゲゼルシャフト	鉄キレート剤と抗新生物剤を含む組合せ剤およびそれらの使用
JP2010504933A (ja)	2006-09-29	2010-02-18	ノバルティスアーゲー	Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
AU2007329375A1 (en)	2006-12-04	2008-06-12	The Board Of Trustees Of The University Of Illinois	Compositions and methods to treat cancer with cupredoxins and CpG rich DNA
CA2677651A1 (en)	2007-02-15	2008-08-21	Novartis Ag	Combinations of therapeutic agents for treating cancer
ES2524259T3 (es)	2008-03-24	2014-12-04	Novartis Ag	Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida
EA019033B1 (ru)	2008-03-26	2013-12-30	Новартис Аг	Ингибиторы дезацетилазы в, основанные на гидроксамате
CN101362784A (zh) *	2008-10-06	2009-02-11	山东大学	埃博霉素苷类化合物和以其为活性成分的组合物及其应用
WO2010083617A1 (en)	2009-01-21	2010-07-29	Oncalis Ag	Pyrazolopyrimidines as protein kinase inhibitors
ES2396023T3 (es)	2009-01-29	2013-02-18	Novartis Ag	Bencimidazoles sustituidos para el tratamiento de astrocitomas
PE20121048A1 (es)	2009-06-26	2012-08-25	Novartis Ag	Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt)	2009-08-12	2016-05-17	Novartis Ag	compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
IN2012DN01453A (he)	2009-08-20	2015-06-05	Novartis Ag
EA201200321A1 (ru)	2009-08-26	2012-09-28	Новартис Аг	Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4
BR112012010519A2 (pt)	2009-11-04	2017-12-05	Novartis Ag	derivados de sulfonamida heterocíclicos
PE20121384A1 (es)	2009-12-08	2012-10-13	Novartis Ag	Derivados de sulfonamida heterociclicos
US8440693B2 (en)	2009-12-22	2013-05-14	Novartis Ag	Substituted isoquinolinones and quinazolinones
CA2927832C (en)	2010-05-18	2021-03-23	Cerulean Pharma Inc.	Cyclodextrin-containing polymer-therapeutic agent conjugates and their use
UA112517C2 (uk)	2010-07-06	2016-09-26	Новартіс Аг	Тетрагідропіридопіримідинові похідні
EP2627648A1 (en)	2010-09-16	2013-08-21	Novartis AG	17aHYDROXYLASE/C17,20-LYASE INHIBITORS
SI2640467T1 (sl)	2010-11-19	2015-04-30	Novartis Ag	Kristalinična oblika inhibitorja interakcije MDM2/4 in P53
CA2824521C (en)	2011-01-20	2016-06-28	Board Of Regents, The University Of Texas System	Mri markers, delivery and extraction systems, and related methods
WO2012107500A1 (en)	2011-02-10	2012-08-16	Novartis Ag	[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
MX359399B (es)	2011-04-28	2018-09-27	Novartis Ag	Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
IN2014DN00123A (he)	2011-06-09	2015-05-22	Novartis Ag
EP2717916B1 (en)	2011-06-10	2017-03-08	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates
EP2721007B1 (en)	2011-06-20	2015-04-29	Novartis AG	Cyclohexyl isoquinolinone compounds
EP2721008B1 (en)	2011-06-20	2015-04-29	Novartis AG	Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
EP2723740A1 (en)	2011-06-27	2014-04-30	Novartis AG	Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
CN102863474A (zh)	2011-07-09	2013-01-09	陈小平	一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
UY34329A (es)	2011-09-15	2013-04-30	Novartis Ag	Compuestos de triazolopiridina
CN102993239A (zh)	2011-09-19	2013-03-27	陈小平	离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
WO2013080141A1 (en)	2011-11-29	2013-06-06	Novartis Ag	Pyrazolopyrrolidine compounds
IN2014CN04174A (he)	2011-12-22	2015-09-04	Novartis Ag
EP2794594A1 (en)	2011-12-22	2014-10-29	Novartis AG	Quinoline derivatives
CA2859873A1 (en)	2011-12-23	2013-06-27	Novartis Ag	Compounds for inhibiting the interaction of bcl2 with binding partners
AU2012355624A1 (en)	2011-12-23	2014-07-17	Novartis Ag	Compounds for inhibiting the interaction of BCL2 with binding partners
EA201491265A1 (ru)	2011-12-23	2014-11-28	Новартис Аг	Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
AU2012355613A1 (en)	2011-12-23	2014-07-17	Novartis Ag	Compounds for inhibiting the interaction of BCL2 with binding partners
AU2012355623A1 (en)	2011-12-23	2014-07-17	Novartis Ag	Compounds for inhibiting the interaction of BCL2 with binding partners
KR101372563B1 (ko) *	2011-12-26	2014-03-14	주식회사 삼양바이오팜	에포틸론 함유물질로부터 에포틸론 ａ와 ｂ의 추출 및 정제 방법
UY34591A (es)	2012-01-26	2013-09-02	Novartis Ag	Compuestos de imidazopirrolidinona
ES2670601T3 (es)	2012-05-15	2018-05-31	Novartis Ag	Derivados de benzamida para la inhibición de la actividad de ABL1, ABL2 y BCR-ABL1
KR20150008406A (ko)	2012-05-15	2015-01-22	노파르티스 아게	Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
MX357305B (es)	2012-05-15	2018-07-04	Novartis Ag	Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1.
WO2013171640A1 (en)	2012-05-15	2013-11-21	Novartis Ag	Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
EP2855483B1 (en)	2012-05-24	2017-10-25	Novartis AG	Pyrrolopyrrolidinone compounds
JP6427097B2 (ja)	2012-06-15	2018-11-21	ザブリガムアンドウィメンズホスピタルインコーポレイテッドＴｈｅＢｒｉｇｈａｍａｎｄＷｏｍｅｎ’ｓＨｏｓｐｉｔａｌ，Ｉｎｃ．	癌を処置するための組成物および該組成物を製造するための方法
ES2654143T3 (es)	2012-10-02	2018-02-12	Gilead Sciences, Inc.	Inhibidores de desmetilasas de histonas
EP2924044B1 (en)	2012-11-17	2018-10-31	Beijing Shuobai Pharmaceutical Co., LTD	Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
TW201422625A (zh)	2012-11-26	2014-06-16	Novartis Ag	二氫－吡啶并－□衍生物之固體形式
WO2014093394A1 (en)	2012-12-10	2014-06-19	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates
US9872918B2 (en)	2012-12-12	2018-01-23	Mersana Therapeutics, Inc.	Hydroxyl-polymer-drug-protein conjugates
JO3464B1 (ar)	2013-01-15	2020-07-05	Astellas Pharma Europe Ltd	التركيبات الخاصة بمركبات التياكوميسين
WO2014115080A1 (en)	2013-01-22	2014-07-31	Novartis Ag	Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en)	2013-01-22	2016-08-02	Novartis Ag	Substituted purinone compounds
WO2014128612A1 (en)	2013-02-20	2014-08-28	Novartis Ag	Quinazolin-4-one derivatives
SG10201707027SA (en)	2013-02-27	2017-09-28	Epitherapeutics Aps	Inhibitors of histone demethylases
US20150018376A1 (en)	2013-05-17	2015-01-15	Novartis Ag	Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
JP2016520665A (ja)	2013-06-11	2016-07-14	バイエル・ファルマ・アクティエンゲゼルシャフト	Ｍｐｓ−１キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
UY35675A (es)	2013-07-24	2015-02-27	Novartis Ag	Derivados sustituidos de quinazolin-4-ona
US9227969B2 (en)	2013-08-14	2016-01-05	Novartis Ag	Compounds and compositions as inhibitors of MEK
WO2015022664A1 (en)	2013-08-14	2015-02-19	Novartis Ag	Compounds and compositions as inhibitors of mek
WO2015022663A1 (en)	2013-08-14	2015-02-19	Novartis Ag	Compounds and compositions as inhibitors of mek
KR20160060100A (ko)	2013-09-22	2016-05-27	칼리토르 사이언시즈, 엘엘씨	치환된 아미노피리미딘 화합물 및 이용 방법
CA2927022C (en)	2013-10-11	2018-08-21	Asana Biosciences, Llc	Protein-polymer-drug conjugates
WO2015054659A1 (en)	2013-10-11	2015-04-16	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates
US9399637B2 (en)	2014-03-28	2016-07-26	Calitor Sciences, Llc	Substituted heteroaryl compounds and methods of use
JP2017512804A (ja)	2014-03-31	2017-05-25	ギリアードサイエンシーズ，インコーポレイテッド	ヒストン脱メチル化酵素の阻害剤
WO2015153345A1 (en)	2014-04-03	2015-10-08	Invictus Oncology Pvt. Ltd.	Supramolecular combinatorial therapeutics
JP2017526675A (ja)	2014-08-27	2017-09-14	ギリアードサイエンシーズ，インコーポレイテッド	ヒストンデメチラーゼを阻害するための化合物および方法
EP3347097B1 (en)	2015-09-11	2021-02-24	Sunshine Lake Pharma Co., Ltd.	Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
US11617799B2 (en)	2016-06-27	2023-04-04	Tagworks Pharmaceuticals B.V.	Cleavable tetrazine used in bio-orthogonal drug activation
US11135307B2 (en)	2016-11-23	2021-10-05	Mersana Therapeutics, Inc.	Peptide-containing linkers for antibody-drug conjugates
US10772971B2 (en)	2017-06-22	2020-09-15	Mersana Therpeutics, Inc.	Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
WO2019099311A1 (en)	2017-11-19	2019-05-23	Sunshine Lake Pharma Co., Ltd.	Substituted heteroaryl compounds and methods of use
EP3740468B1 (en)	2018-01-20	2025-12-31	Sunshine Lake Pharma Co., Ltd.	Substituted Aminopyrimidine Compounds and Methods of Use
AU2019262521B2 (en)	2018-05-04	2024-04-18	Tagworks Pharmaceuticals B.V.	Compounds comprising a linker for increasing transcyclooctene stability
CA3099419A1 (en)	2018-05-04	2019-11-07	Tagworks Pharmaceuticals B.V.	Tetrazines for high click conjugation yield in vivo and high click release yield
CA3117050A1 (en)	2018-10-29	2020-05-07	Mersana Therapeutics, Inc.	Cysteine engineered antibody-drug conjugates with peptide-containing linkers
FR3087650B1 (fr)	2018-10-31	2021-01-29	Bio Even	Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer
IL289094A (he)	2019-06-17	2022-02-01	Tagworks Pharmaceuticals B V	טטראזינים עבור הגברת המהירות והתפוקה של תגובת " שחרור בקליק"
WO2020256546A1 (en)	2019-06-17	2020-12-24	Tagworks Pharmaceuticals B.V.	Compounds for fast and efficient click release
EP4399283A2 (en)	2021-09-06	2024-07-17	Veraxa Biotech GmbH	Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
DK4186529T3 (da)	2021-11-25	2025-08-25	Veraxa Biotech Gmbh	Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse
JP2024543916A (ja)	2021-11-25	2024-11-26	ヴェラクサバイオテックゲーエムベーハー	遺伝暗号拡張を利用した部位特異的結合によって調製された改良された抗体ペイロード複合体（ａｐｃ）
KR20240119102A (ko)	2021-12-08	2024-08-06	유럽피안 몰레큘러 바이올로지 래보러토리	표적화 접합체의 제조를 위한 친수성 테트라진-관능화 페이로드
EP4372000B1 (en)	2022-02-15	2026-06-17	Tagworks Pharmaceuticals B.V.	Masked il12 protein
KR20250049568A (ko)	2022-07-15	2025-04-11	페온 테라퓨틱스 리미티드	Cdcp1에 결합하는 항체 약물 접합체 및 이의 용도
IL320221A (he)	2022-10-12	2025-06-01	Tagworks Pharmaceuticals B V	ביצילקלו-נוננים מתוחים
CN120569216A (zh)	2023-01-20	2025-08-29	巴斯夫欧洲公司	稳定型生物聚合物组合物、其制造和用途
JP2026509291A (ja)	2023-03-10	2026-03-17	タグワークスファーマシューティカルスビー．ブイ．	向上されたｔ－リンカーを有するトランス－シクロオクテン
EP4750750A1 (en)	2023-07-27	2026-06-03	Veraxa Biotech GmbH	Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same
EP4512395A1 (en)	2023-08-21	2025-02-26	Bio Even	Composition comprising flavin adenine dinucleotide (fad), l-gsh, atp and myristic acid, alone or with a drug
CN122206462A (zh)	2023-09-15	2026-06-12	巴斯夫欧洲公司	稳定型生物聚合物组合物、其制造和用途
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof
WO2025174248A1 (en)	2024-02-16	2025-08-21	Tagworks Pharmaceuticals B.V.	Trans-cyclooctenes with "or gate" release
TW202617187A (zh)	2024-08-22	2026-05-01	荷蘭商泰格沃克斯製藥有限公司	反-環辛烯調配物
WO2026078060A1 (en)	2024-10-08	2026-04-16	Basf Se	Tocopherol alkoxylates for biopolymer stabilization
WO2026139575A1 (en)	2024-12-23	2026-07-02	Veraxa Biotech Gmbh	Novel tco-functionalized glycan engineered immunoglobulin molecules, novel tco-functionalized saccharide compounds for preparing the same, and novel antibody payload conjugates

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0358606A3 (de)	1988-09-09	1990-10-31	Gesellschaft für Biotechnologische Forschung mbH (GBF)	Mikrobiologisches Verfahren zur Herstellung agrarchemisch verwendbarer mikrobizider makrozyklischer Lactonderivate
GB8909737D0 (en) *	1989-04-27	1989-06-14	Shell Int Research	Thiazole derivatives
DE4138042C2 (de) *	1991-11-19	1993-10-14	Biotechnolog Forschung Gmbh	Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
RU2143896C1 (ru) *	1993-03-05	2000-01-10	Хексаль Аг	Кристаллический комплекс циклодекстрина с гидрохлоридом ранитидина, способ его получения и содержащие его фармацевтические составы
EP0739339A1 (en)	1994-01-11	1996-10-30	The Scripps Research Institute	Chemical switching of taxo-diterpenoids between low solubility active forms and high solubility inactive forms
DE19639456A1 (de)	1996-09-25	1998-03-26	Biotechnolog Forschung Gmbh	Epothilon-Derivate, Herstellung und Mittel
DE19542986A1 (de) *	1995-11-17	1997-05-22	Biotechnolog Forschung Gmbh	Epothilon-Derivate und deren Verwendung
DE59609305D1 (de)	1995-11-17	2002-07-11	Biotechnolog Forschung Gmbh	Epothilon-Derivate und deren Herstellung
DE19645362A1 (de)	1996-10-28	1998-04-30	Ciba Geigy Ag	Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19645361A1 (de)	1996-08-30	1998-04-30	Ciba Geigy Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
US5969145A (en) *	1996-08-30	1999-10-19	Novartis Ag	Process for the production of epothilones and intermediate products within the process
AU716610B2 (en)	1996-08-30	2000-03-02	Novartis Ag	Method for producing epothilones, and intermediate products obtained during the production process
DE19636343C1 (de)	1996-08-30	1997-10-23	Schering Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
ATE267197T1 (de)	1996-11-18	2004-06-15	Biotechnolog Forschung Gmbh	Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6515016B2 (en)	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en) *	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
EP1386922B1 (en)	1996-12-03	2012-04-11	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US6660758B1 (en)	1996-12-13	2003-12-09	The Scripps Research Institute	Epothilone analogs
US6380394B1 (en) *	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
DE19701758A1 (de)	1997-01-20	1998-07-23	Wessjohann Ludgar A Dr	Epothilone-Synthesebausteine
EP0975638B1 (de) *	1997-02-25	2002-08-07	Gesellschaft für biotechnologische Forschung mbH (GBF)	Seitenkettenmodifizierte epothilone
US5828449A (en)	1997-02-26	1998-10-27	Acuity Imaging, Llc	Ring illumination reflective elements on a generally planar surface
DE19713970B4 (de)	1997-04-04	2006-08-31	R&D-Biopharmaceuticals Gmbh	Epothilone-Synthesebausteine II - Prenylderivate
JP4065573B2 (ja)	1997-04-18	2008-03-26	ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス
DE19720312A1 (de)	1997-05-15	1998-11-19	Hoechst Ag	Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de)	1997-05-15	1998-11-19	Biotechnolog Forschung Gmbh	Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de)	1997-06-17	1998-12-24	Schering Ag	Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
DK1001951T3 (da)	1997-07-16	2002-12-23	Schering Ag	Thiazolderivater, fremgangsmåde til fremstilling deraf og anvendelse af disse
ES2290993T3 (es)	1997-08-09	2008-02-16	Bayer Schering Pharma Aktiengesellschaft	Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
KR20080016756A (ko)	1998-02-05	2008-02-21	노파르티스 아게	유기화합물 함유 조성물
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr)	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
CA2322157C (en)	1998-02-25	2012-05-29	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
DE19826988A1 (de) *	1998-06-18	1999-12-23	Biotechnolog Forschung Gmbh	Epothilon-Nebenkomponenten
AU5036999A (en)	1998-06-30	2000-01-17	Schering Aktiengesellschaft	Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
US6410301B1 (en) *	1998-11-20	2002-06-25	Kosan Biosciences, Inc.	Myxococcus host cells for the production of epothilones
CN100381566C (zh)	1998-11-20	2008-04-16	科森生物科学公司	产生环氧噻酮及其衍生物的重组方法和材料
BR9916833A (pt)	1998-12-22	2001-09-25	Novartis Ag	Derivados de epotilona e seu uso como agentes antitumor
US6780620B1 (en)	1998-12-23	2004-08-24	Bristol-Myers Squibb Company	Microbial transformation method for the preparation of an epothilone
US6596875B2 (en) *	2000-02-07	2003-07-22	James David White	Method for synthesizing epothilones and epothilone analogs
EE200100431A (et)	1999-02-18	2002-12-16	Schering Aktiengesellschaft	16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
EE04852B1 (et) *	1999-02-22	2007-06-15	Gesellschaft Fuer Biotechnologische Forschung Mbh	C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel
US6211412B1 (en) *	1999-03-29	2001-04-03	The University Of Kansas	Synthesis of epothilones
AR023792A1 (es)	1999-04-30	2002-09-04	Bayer Schering Pharma Ag	Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
TWI310684B (en) *	2000-03-27	2009-06-11	Bristol Myers Squibb Co	Synergistic pharmaceutical kits for treating cancer
US6489314B1 (en) *	2001-04-03	2002-12-03	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
US6589968B2 (en) *	2001-02-13	2003-07-08	Kosan Biosciences, Inc.	Epothilone compounds and methods for making and using the same
US6906188B2 (en) *	2001-04-30	2005-06-14	State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University	Method for synthesizing epothilones and epothilone analogs
WO2003029195A1 (en) *	2001-09-28	2003-04-10	Sumika Fine Chemicals Co., Ltd.	Intermediates for epothilone derivative and process for producing these
US6884608B2 (en) *	2001-12-26	2005-04-26	Bristol-Myers Squibb Company	Compositions and methods for hydroxylating epothilones
TW200303202A (en)	2002-02-15	2003-09-01	Bristol Myers Squibb Co	Method of preparation of 21-amino epothilone derivatives
US6921769B2 (en) *	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
HRP20050278A2 (en)	2002-09-23	2005-10-31	Bristol-Myers Squibb Company	Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b

1997
- 1997-11-18 AT AT97951233T patent/ATE267197T1/de active
- 1997-11-18 HU HU0000497A patent/HU229833B1/hu unknown
- 1997-11-18 IL IL12955897A patent/IL129558A/he not_active IP Right Cessation
- 1997-11-18 AU AU54837/98A patent/AU753546B2/en not_active Expired
- 1997-11-18 EP EP97951233A patent/EP0941227B2/de not_active Expired - Lifetime
- 1997-11-18 WO PCT/EP1997/006442 patent/WO1998022461A1/de not_active Ceased
- 1997-11-18 JP JP52320898A patent/JP4274583B2/ja not_active Expired - Lifetime
- 1997-11-18 CZ CZ20041118A patent/CZ303422B6/cs not_active IP Right Cessation
- 1997-11-18 DK DK03016552T patent/DK1367057T3/da active
- 1997-11-18 DK DK97951233T patent/DK0941227T5/da active
- 1997-11-18 CN CNB2005100062827A patent/CN100344627C/zh not_active Expired - Lifetime
- 1997-11-18 CN CNB971998140A patent/CN1196698C/zh not_active Expired - Lifetime
- 1997-11-18 PL PL333435A patent/PL193229B1/pl unknown
- 1997-11-18 CZ CZ0175099A patent/CZ296164B6/cs not_active IP Right Cessation
- 1997-11-18 CA CA2269118A patent/CA2269118C/en not_active Expired - Lifetime
- 1997-11-18 ES ES03016552T patent/ES2312695T3/es not_active Expired - Lifetime
- 1997-11-18 AT AT03016552T patent/ATE408612T1/de active
- 1997-11-18 RU RU99113031/04A patent/RU2198173C2/ru active
- 1997-11-18 DE DE59712968T patent/DE59712968D1/de not_active Expired - Lifetime
- 1997-11-18 EP EP03016552A patent/EP1367057B1/de not_active Expired - Lifetime
- 1997-11-18 NZ NZ335383A patent/NZ335383A/xx not_active IP Right Cessation
- 1997-11-18 BR BRPI9713363-9A patent/BR9713363B1/pt not_active IP Right Cessation
- 1997-11-18 DE DE59711647T patent/DE59711647D1/de not_active Expired - Lifetime
- 1997-11-18 PT PT03016552T patent/PT1367057E/pt unknown
- 1997-11-18 KR KR10-1999-7004302A patent/KR100538095B1/ko not_active Expired - Lifetime
- 1997-11-18 PT PT97951233T patent/PT941227E/pt unknown
- 1997-11-18 ES ES97951233T patent/ES2221692T5/es not_active Expired - Lifetime
1998
- 1998-01-21 TW TW086117334A patent/TW408119B/zh not_active IP Right Cessation
1999
- 1999-05-14 NO NO19992338A patent/NO319984B1/no not_active IP Right Cessation
2004
- 2004-11-12 US US10/988,328 patent/US7067544B2/en not_active Expired - Fee Related
2005
- 2005-10-26 CY CY0500058A patent/CY2542B1/xx unknown
2006
- 2006-04-27 US US11/412,536 patent/US20060264482A1/en not_active Abandoned
2008
- 2008-04-28 US US12/110,781 patent/US20080293784A1/en not_active Abandoned
2009
- 2009-03-24 US US12/409,823 patent/US7846952B2/en not_active Expired - Fee Related
- 2009-05-01 US US12/434,078 patent/US7759375B2/en not_active Expired - Fee Related
2010
- 2010-12-06 US US12/961,447 patent/US8076490B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE59711647D1 (de)	2004-06-24
CN100344627C (zh)	2007-10-24
EP0941227B9 (de)	2005-05-04
US7067544B2 (en)	2006-06-27
NZ335383A (en)	2000-10-27
ES2221692T3 (es)	2005-01-01
BR9713363B1 (pt)	2011-02-08
ES2312695T3 (es)	2009-03-01
HUP0000497A3 (en)	2001-10-29
PL193229B1 (pl)	2007-01-31
DK0941227T5 (da)	2009-10-05
NO992338D0 (no)	1999-05-14
CN1196698C (zh)	2005-04-13
HK1022314A1 (en)	2000-08-04
KR20000053308A (ko)	2000-08-25
US20090270466A1 (en)	2009-10-29
JP4274583B2 (ja)	2009-06-10
TW408119B (en)	2000-10-11
IL129558A0 (en)	2000-02-29
AU5483798A (en)	1998-06-10
US20050090535A1 (en)	2005-04-28
RU2198173C2 (ru)	2003-02-10
KR100538095B1 (ko)	2005-12-21
ATE408612T1 (de)	2008-10-15
EP0941227B1 (de)	2004-05-19
EP1367057A1 (de)	2003-12-03
JP2001504474A (ja)	2001-04-03
DK1367057T3 (da)	2009-01-19
US20090247592A1 (en)	2009-10-01
PT1367057E (pt)	2008-12-04
NO992338L (no)	1999-05-14
US7759375B2 (en)	2010-07-20
US20060264482A1 (en)	2006-11-23
US20110136185A1 (en)	2011-06-09
US7846952B2 (en)	2010-12-07
CZ296164B6 (cs)	2006-01-11
AU753546B2 (en)	2002-10-24
EP1367057B1 (de)	2008-09-17
CZ175099A3 (cs)	1999-09-15
CN1237970A (zh)	1999-12-08
US8076490B2 (en)	2011-12-13
DK0941227T3 (da)	2004-06-28
ES2221692T4 (es)	2005-10-01
EP0941227B2 (de)	2009-10-14
PT941227E (pt)	2004-08-31
EP0941227A1 (de)	1999-09-15
CY2542B1 (en)	2006-06-28
ATE267197T1 (de)	2004-06-15
PL333435A1 (en)	1999-12-06
NO319984B1 (no)	2005-10-10
ES2221692T5 (es)	2009-12-14
BR9713363A (pt)	2000-01-25
CN1680370A (zh)	2005-10-12
WO1998022461A1 (de)	1998-05-28
CZ303422B6 (cs)	2012-09-05
CA2269118A1 (en)	1998-05-28
DK0941227T4 (da)	2008-05-19
HK1083832A1 (zh)	2006-07-14
CA2269118C (en)	2012-05-29
US20080293784A1 (en)	2008-11-27
HU229833B1 (en)	2014-09-29
DE59712968D1 (de)	2008-10-30
HUP0000497A2 (hu)	2000-06-28

Legal Events

Date	Code	Title
2002-06-30	KB	Patent renewed
2004-02-08	KB	Patent renewed
2008-01-06	KB	Patent renewed
2011-12-29	KB	Patent renewed
2015-11-30	KB	Patent renewed
2018-06-28	EXP	Patent expired

Publication	Publication Date	Title
AU753546B2 (en)	2002-10-24	Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
US6288237B1 (en)	2001-09-11	Epothilons C and D, preparation and compositions
Wu et al.	2006	N-carboxamido-staurosporine and selina-4 (14), 7 (11)-diene-8, 9-diol, new metabolites from a marine Streptomyces sp.
KR100300152B1 (ko)	2001-09-06	디벤조-옥사제핀과 디벤조-디옥세핀유도체,및 항종양제로서의 이들의 용도
EP0329361B1 (en)	1995-12-06	2-pyranone derivatives and process for production thereof
Anke et al.	1987	Antibiotics from basidiomycetes. 26 Phlebiakauranol aldehyde an antifungal and cytotoxic metabolite from Punctularia atropurpurascens
KR20050019892A (ko)	2005-03-03	에포틸론 씨, 디, 이 및 에프, 그 제조방법 및 세포증식억제제와 식물 위생제로서의 이들의 용도
MXPA99004471A (en)	2001-12-04	Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
CN121975634A (zh)	2026-05-05	一种里氏木霉hk1-12及其次级代谢产物与应用
HK1022314B (en)	2005-10-21	Epothilone d, e and f, production process,and their use as cytostatic as well as phytosanitary agents
HK1083832B (en)	2008-03-20	Epothilone c,production process,and their use as cytostatic as well as phytosanitary agents